What factors drove the changes in Arvinas's revenue and profit?

What guidance did Arvinas's management provide for the next earnings period?

What does Arvinas do and what are its main business segments?

What were the key takeaways from Arvinas's earnings call?

What is the revenue and EPS growth rate for Arvinas year over year?

What is Arvinas's latest dividend and current dividend yield?

What is the market's earnings forecast for Arvinas next quarter?

What were the key takeaways from Arvinas’s earnings call?

**【Key Takeaways】**
- **Pipeline Momentum**: ARV-102 and ARV-393 show promising Phase I data, with ARV-102 targeting neurodegenerative diseases and ARV-393 demonstrating early lymphoma responses.
- **KRAS G12D Leadership**: ARV-806 outperforms competitors with 25x potency, positioning for 2026 clinical readouts.
- **Financial Strength**: $787.6 million cash runway supports pipeline through 2028, with cost reductions maintaining quarterly spend below $75 million.
- **Strategic Partnerships**: Pfizer collaboration for vepdegestrant and Novartis for luxdegalutamide expand commercial reach.
- **Upcoming Catalysts**: Phase I trials for ARV-027 (SBMA) and ARV-6723 (HPK1) in 2026, with ASH and SITC data updates.

**【CEO Opening Remarks】**
- Highlighted progress across clinical programs, including ARV-102 (LRRK2 degrader) and ARV-393 (BCL6 degrader), with multiple data readouts expected in 2026.
- Announced partnership with Pfizer to commercialize vepdegestrant, with FDA PDUFA date set for June 2026.
- Emphasized financial flexibility with $787.6 million in cash as of Q3 2025, supporting pipeline through H2 2028.

**【CMO (Noah Berkowitz) Presentation】**
- ARV-102: Phase I data shows 90% LRRK2 reduction in healthy volunteers and 86-97% reduction in Parkinson's patients, with biomarker improvements in lysosomal and neuroinflammatory pathways.
- ARV-393: Early Phase I responses in B- and T-cell lymphomas at sub-therapeutic doses, with plans to initiate combination trials with CD20-targeted therapies in 2026.

**【CSO (Angela Cacace) Presentation】**
- ARV-806 (KRAS G12D degrader): Preclinical data shows 25x greater potency than competitors, with tumor regressions in multiple models.
- ARV-027 (polyQ-AR degrader): Preclinical efficacy in SBMA, with Phase I trials expected in 2026.
- ARV-6723 (HPK1 degrader): Immuno-oncology candidate showing superior activity to anti-PD-1 in preclinical studies.

**【CFO (Andrew Saik) Financial Update】**
- Q3 2025 cash balance: $787.6 million (down from $1.04 billion in Q4 2024) due to vepdegestrant partnership with Novartis.
- Non-GAAP R&D expenses: $56.9 million (down 22% YoY), with plans to maintain quarterly spend below $75 million.
- Share buyback program: $100 million authorized, with 2.56 million shares repurchased at $7.91 average price.

**【Q&A Highlights】**
- **ARV-393 Differentiation**: Monotherapy activity in T-cell lymphomas and combination potential with bispecifics for DLBCL.
- **KRAS G12D Tolerability**: ARV-806's potency and brain penetration may avoid liver toxicity seen with competitors.
- **Pipeline Strategy**: Focus on early-stage programs with high differentiation, including neuromuscular and immuno-oncology assets.
- **Vepdegestrant Update**: Pfizer seeking partner for commercialization, with FDA review ongoing.


Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript

- **Pipeline Progress**: ARV-102, ARV-393, and ARV-806 advance into Phase I with differentiated preclinical activity; ARV-102 shows deep brain penetration in humans.
- **Vepdeg Restructuring**: Collaboration with Pfizer under renegotiation; potential external partnership if rights returned.
- **Financial Resilience**: $861M cash balance with runway to 2028; R&D expenses reduced by 25% YoY.
- **Strategic Shifts**: Focus on high-value assets (neuro-oncology, KRAS) while optimizing commercial infrastructure.
- **AI Integration**: Accelerating PROTAC design and clinical operations efficiency.

**【Management Opening Remarks】**
- Arvinas reported strong clinical momentum in Q2 2025, including Phase I trials for neuro and oncology assets (ARV-806, ARV-102, ARV-393) and first-in-human data for ARV-102.
- The company completed a restructuring to extend cash runway into H2 2028, reducing workforce by ~33% and reprioritizing R&D programs.
- Key imperatives: advancing vepdeg to launch, achieving clinical milestones, and efficient capital allocation.
- CEO transition announced, with search for new CEO underway.

**【CEO Commentary】**
- Vepdeg NDA submission completed, targeting second-line monotherapy in ER+/HER2- metastatic breast cancer.
- Collaboration with Pfizer restructured; potential return of vepdeg rights to Arvinas for external partnership.
- Pipeline highlights:
  - ARV-102 (LRRK2 degrader) shows deep brain penetration, with Phase I data expected later this year.
  - ARV-393 (BCL6 degrader) demonstrates efficacy in lymphoma models, with Phase I trial ongoing.
  - ARV-806 (KRAS G12D degrader) enters clinic with ~25x potency vs. KRAS inhibitors.
- Luxdegalutamide (licensed to Novartis) advancing in Phase II trials for prostate cancer.

**【CFO Financial Commentary】**
- Q2 2025 cash balance: $861.2M (down from $1.04B at end of 2024 due to reduced Novartis and Pfizer collaboration revenue).
- R&D expenses: $68.6M (down 25% YoY due to vepdeg and luxdegalutamide program reductions).
- Restructuring costs: $7.4M in Q2, with full benefits realized from Q3 2025.
- Cash runway extended to H2 2028 through cost reductions and program reprioritization.

**【Q&A Highlights】**
- ARV-102: Parkinson's disease Phase I data expected later this year, focusing on CSF LRRK2 degradation and safety.
- Vepdeg: Potential partner sought if Pfizer returns rights; launch readiness activities minimal.
- KRAS pipeline: ARV-806 Phase I progressing rapidly, with preclinical data showing resistance to KRAS resynthesis.
- BCL6 strategy: Prioritize combination trials with CD20-targeted therapies in DLBCL.
- AI utilization: Accelerating PROTAC design, clinical operations efficiency, and biomarker analysis.

Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript

- **VEPDEG Regulatory Momentum**: Phase 3 data supports 2025 regulatory filing for second-line ESR1 mutant breast cancer; ~25,000 annual US patients addressable.
- **Cost Restructuring Success**: $80M annual savings extend cash runway to 2028; 33% workforce reduction streamlines operations.
- **Pipeline Progress**: ARV-102 shows >50% LRRK2 degradation in Parkinson's phase 1; ARV-806 KRAS degrader 30x more potent than competitors.
- **Strategic Focus**: Shift to high-value assets like neurodegenerative and hematologic degraders; Pfizer collaboration for VEPDEG commercialization.

**【CEO Summary Section】**
- Announced positive phase 3 data for VEPDEG in ESR1 mutant metastatic breast cancer, with plans for regulatory filing in 2025. Removed two phase 3 combination trials with Pfizer due to evolving treatment landscape and capital allocation priorities.
- Implemented a workforce reduction of ~33% and annualized cost savings of $80 million, extending cash runway to H2 2028. Reprioritized pipeline to focus on ARV-102 (LRRK2 degrader for neurodegenerative diseases) and ARV-393 (BCL6 degrader for hematologic malignancies).
- Highlighted progress in KRAS G12D degrader ARV-806, with preclinical data showing 30x potency vs. competitors and plans for phase 1 trial in 2025.

**【CFO Financial Commentary】**
- Q1 2025 revenue: $188.8M (vs. $25.3M in Q1 2024), driven by percentage-of-completion accounting for VEPDEG collaboration with Pfizer.
- R&D expenses: $90.8M (vs. $84.3M in Q1 2024), including $10M one-time inventory charge for VEPDEG.
- Cash balance: $954M as of March 31, 2025, with updated cash runway to H2 2028 after restructuring.

**【Q&A Highlights】**
- VEPDEG positioning: Expected to be best-in-class monotherapy for ESR1 mutant patients in second-line setting; ~25,000 annual addressable patients in US.
- Neurology pipeline: ARV-102 phase 1 data in Parkinson's disease shows >50% LRRK2 protein degradation in CSF; plans for phase 1/2 study in PSP in 2025.
- Commercial strategy: 50-50 co-commercialization with Pfizer in US; minimal upfront infrastructure, data-driven build-out post-approval.
- KRAS degrader: ARV-806 preclinical data shows superior potency vs. inhibitors; phase 1 trial targeting pancreatic and colorectal cancers.


Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript

- **VEPDEG Milestone**: Phase 3 topline results expected Q1 2025; combination trials with atirmociclib (first-line) and CDK4/6 inhibitors (second-line) planned for 2025.
- **Neuro Pipeline Breakthrough**: ARV-102 first-in-human data in Parkinson’s disease to be presented at AD/PD 2025; Phase 1 trial in PSP and PD ongoing.
- **KRAS G12D Potential**: IND filing planned for 2025; preclinical data shows 40x potency vs. competitors.
- **Financial Strength**: $1.0B cash balance supports operations into 2027; 2024 revenue up 238% YoY to $263.4M.


**【CEO Overview】**
- Highlighted progress of the PROTAC platform, with vepdegestrant (vepdeg) Phase 3 trial results expected later this quarter.
- Vepdeg, a first-in-class ER-targeting PROTAC, is being developed with Pfizer for metastatic breast cancer, with plans for combination trials in first- and second-line settings.
- Expanded pipeline includes ARV-102 (LRRK2 degrader) for neurodegenerative diseases and ARV-393 (BCL6 degrader) for non-Hodgkin lymphoma.
- KRAS G12D degrader IND filing planned for 2025.

**【CFO Financial Update】**
- Q4 2024 revenue: $59.2M (vs. -$43.1M in Q4 2023), driven by contract adjustments.
- Full-year 2024 revenue: $263.4M (vs. $78.5M in 2023).
- R&D expenses: $83.3M (Q4) and $348.2M (full year), down 11.9% YoY due to out-licensing.
- G&A expenses: $34.1M (Q4) and $165.4M (full year), up 26.4% YoY for commercial prep.
- Cash balance: $1.0B as of Q4 2024, supporting operations into 2027.

**【Key Pipeline Updates】**
- **Vepdeg**: Phase 3 VERITAC-2 topline results expected Q1 2025; combination trials with atirmociclib (first-line) and CDK4/6 inhibitors (second-line) planned for 2025.
- **ARV-102**: First-in-human data in Parkinson’s disease to be presented at AD/PD 2025; Phase 1 trial in PSP and PD ongoing.
- **ARV-393**: BCL6 degrader Phase 1 trial enrolling; AACR 2025 to feature preclinical data on monotherapy and combinations.
- **KRAS G12D**: IND filing planned for 2025; preclinical data shows 40x potency vs. competitors.

**【Q&A Highlights】**
- **Commercial Prep**: Interim Chief Commercial Officer leading efforts; Pfizer collaboration for U.S. launch.
- **VEPDEG Combination Trials**: Atirmociclib chosen for first-line due to safety and efficacy profiles; Phase 3 design to be finalized post-regulatory feedback.
- **ARV-102 Neurodegenerative Potential**: Targeting LRRK2 in PSP and PD; 50% protein degradation threshold guided by preclinical data.
- **KRAS G12D Differentiation**: Catalytic mechanism binds active/inactive states; neoantigen induction distinct from inhibitors.


ARVN

ARVN fundamentals

Earnings Call

You can ask Aime